Parkinson's Disease Support Group
Parkinson's disease is a movement disorder often characterized by muscle rigidity, tremor, a slowing of physical movement, and in extreme cases, a loss of physical movement. The primary symptoms of Parkinsons are due to excessive muscle contraction, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the...
I have been taking Azilect since the beginning of January 2013. Since then my symptoms have not changed and I have had a slight decrease in the amount of Sinemet I have been taking. I have no experience with Seleglline, so I could not say if they are interchangeable.
At the time I started taking Azilect, I had no insurance. My neuro suggested I apply for a program offered by Teva Neuroscience to help PD patients pay for the drug. I completed the app and returned it to the doctor who submitted it to the program. During my time in the program there was some discussion of offering coupons for those who were entering the "donut hole" with Medicare.
Here are 2 web sites you can check for information, www.azilect.com and www.parkinsonssupportssolutions.com and a phone number for Patient Support Solutions is 1.866.880.8582.
Best of luck to you, I hope this helps.
Madge
www.azilect.com
www.parkinsonssupportsolutions.com
I those don't work, the phone number should be good.
You know the bigger issue is why aren't the foundations working on getting the cost of meds reduced by getting the patent and exclusivity rules changed so the market can set the price. I researched getting my Azilect from a Canadian Rx and found it available for $US 300 and easy to obtain as long as your doctor will write you a paper Rx and was okay with having it filled in Canada.
Azilect is rasagaline. Selegiline is Eldepryl and Zelapar
I AM NOT A DR. NOR DO I PLAY ONE ON TV --
This link is to the NIH health info on Selegiline:
http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697046.html#brand-name-1
The donut hole is indeed a sucking vortex! PLEASE READ THE FOLLOWING BELOW:
Sep. 23, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the U.S. District Court for the District of New Jersey has issued a favorable ruling in the Companys patent infringement lawsuit against Mylan regarding an AZILECT (rasagiline tablets) patent which covers methods of treating Parkinsons disease (PD). The Court has upheld the validity of Tevas patent. Teva anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect until Tevas patent expires in 2017.
Prayers for your relief, and that you try not to worry too much about taking the meds you need despite the cost.